Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) - Investment analysts at HC Wainwright lowered their Q1 2025 earnings per share estimates for shares of Abeona Therapeutics in a note issued to investors on Monday, March 24th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($0.36) per share for the quarter, down from their previous forecast of ($0.34). HC Wainwright has a "Buy" rating and a $15.00 price objective on the stock. The consensus estimate for Abeona Therapeutics' current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Abeona Therapeutics' Q3 2025 earnings at ($0.29) EPS, Q4 2025 earnings at ($0.13) EPS and FY2025 earnings at ($1.11) EPS.
A number of other brokerages also recently issued reports on ABEO. Oppenheimer initiated coverage on Abeona Therapeutics in a report on Wednesday, March 5th. They issued an "outperform" rating and a $16.00 price target on the stock. StockNews.com raised shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a research report on Monday, March 24th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $17.50.
View Our Latest Research Report on Abeona Therapeutics
Abeona Therapeutics Trading Down 1.4 %
NASDAQ:ABEO traded down $0.07 during midday trading on Wednesday, hitting $4.97. The stock had a trading volume of 529,297 shares, compared to its average volume of 408,282. The company has a market capitalization of $241.21 million, a price-to-earnings ratio of -1.85 and a beta of 1.79. Abeona Therapeutics has a one year low of $3.05 and a one year high of $8.45. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The stock has a 50-day moving average of $5.42 and a 200 day moving average of $5.81.
Abeona Therapeutics (NASDAQ:ABEO - Get Free Report) last posted its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.19.
Institutional Investors Weigh In On Abeona Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Twinbeech Capital LP acquired a new stake in Abeona Therapeutics in the 4th quarter worth approximately $58,000. Squarepoint Ops LLC acquired a new position in shares of Abeona Therapeutics in the 4th quarter valued at $67,000. Jane Street Group LLC purchased a new position in Abeona Therapeutics in the 3rd quarter worth $84,000. Oxford Asset Management LLP acquired a new stake in Abeona Therapeutics during the 4th quarter worth about $118,000. Finally, Charles Schwab Investment Management Inc. purchased a new stake in Abeona Therapeutics during the 3rd quarter valued at about $151,000. Institutional investors and hedge funds own 80.56% of the company's stock.
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Further Reading

Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for April 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.